|Base Year Market Size
|USD 455 Million
|Forecast Year Market Size
|USD 768 Million
|Fastest Growing Market
The global paraneoplastic syndrome market size was valued at USD 455 million in 2022 and is projected to reach USD 768 million by 2031, registering a CAGR of 6.0% during the forecast period (2023-2031). The growing elderly population and rising cancer prevalence are the primary factors impacting the paraneoplastic syndrome market share.
Paraneoplastic syndromes (PNS) are rare disorders that emerge due to an aberrant immune system response to a neoplasm (tumor), most commonly of the nerve system. These syndromes are distinguished by a wide range of signs and symptoms that are not directly produced by the tumor or its metastases but result from the immune system's reaction to the presence of cancer.
The rising cancer prevalence and growing geriatric population are the primary factors impacting market growth. Furthermore, rising healthcare spending, rising government funding, and rising activities by public and private organizations to raise disease awareness will propel the paraneoplastic syndrome market forward. Other reasons, such as an increase in breast cancer incidence, excessive tobacco consumption, and an unhealthy lifestyle, would dampen the Paraneoplastic Syndrome market growth.
The occurrence of cancer is closely connected to the prevalence of paraneoplastic disorders. Paraneoplastic syndromes are frequently caused by the immune system's response to an underlying neoplasm (tumor). As a result, an increase in the global incidence of cancer cases may indirectly lead to an increase in the prevalence of paraneoplastic syndromes. Global cancer incidence climbed from an anticipated 18.1 million new cases in 2018 to more than 19.3 million in 2020, according to the World Health Organization (WHO). Certain kinds of cancer may be more typically associated with paraneoplastic disorders. A rise in the occurrence of certain tumors may contribute to a higher prevalence of paraneoplastic syndromes. Lung cancer is expected to account for 1,03,371 occurrences in 2022, ranking in the top five primary sites for both males and females. The International Agency for Research on Cancer (IARC) GLOBOCAN 2020 estimates of cancer incidence and mortality show that lung cancer is the top cause of cancer death, with an anticipated 1.8 million deaths (18%) in 2020.
Furthermore, the aging population is frequently connected to an increased risk of cancer. With a growing older population worldwide, the global cancer burden is expected to climb. Demographic estimates show that the global aging population will grow significantly. According to the UN, the number of individuals aged 60 and older is predicted to double by 2050. As a result, these variables are projected to impact the Paraneoplastic Syndrome market trend.
The high cost of treatment for paraneoplastic syndromes may be influenced by several factors, including the condition's rarity, the difficulty of creating targeted medicines, and the small patient group. Paraneoplastic syndromes are considered rare disorders since they affect a limited number of people. The small patient population can make it difficult for pharmaceutical corporations to recoup R&D investments.
Furthermore, developing targeted therapeutics for paraneoplastic diseases necessitates large R&D resources. The immune system's complexity and the necessity for novel treatments may contribute to higher R&D expenses. Furthermore, treatments for paraneoplastic disorders may necessitate specific techniques, such as immunomodulatory medications or other novel interventions. The discovery and manufacturing of these specialty medicines can be costly.
As we better understand the immunological pathways driving paraneoplastic diseases, there may be more chances for study and development. This encompasses the discovery of new therapeutic targets and the creation of more effective medicines. The most frequent PNSs are Lambert-Eaton Myasthenic Syndrome (LEMS), which affects 3.8% of SCLC patients, and myasthenia gravis (MG), roughly 39% of thymoma patients. According to one prospective study, 9.4% of SCLC patients have one or more paraneoplastic syndromes, the most prevalent of which are LEMS, sensory neuropathy, and limbic encephalitis. The primary tumor will proclaim itself and be diagnosed in over 90% of individuals with PNS and solid tumors within one year of the onset of PNS.
However, in some cases, the predicted tumor is not detected until several years after the onset of neurologic symptoms. A single area prospective investigation on 264 patients with biopsy-proven SCLC in the United Kingdom found that the disease frequency of PNS was substantially higher than expected, at 9.4%, implying that PNS may be underdiagnosed in SCLC patients. As a result, additional studies can fuel market expansion in the future.
The global paraneoplastic syndrome market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.
North America is the most significant global paraneoplastic syndrome market shareholder and is estimated to grow at a CAGR of 5.9% over the forecast period. The market expansion in this particular geographical area can be ascribed to the rising number of elderly individuals affected by paraneoplastic illness, augmented investments in research and development, and technological breakthroughs. For example, in 2022, approximately 17.3 percent of the population in the United States was 65 years or older. This represents a notable increase compared to previous years, and it is projected that this proportion will further rise to 22 percent by the year 2050.
Likewise, it is estimated that the United States will experience 1,918,030 new instances of cancer and 609,360 cancer-related deaths in the year 2022. Notably, lung cancer, which stands as the primary cause of cancer mortality, is expected to account for nearly 350 deaths every day. The anticipated increase in cancer incidence and mortality rates is projected to have a significant influence on the market. However, the growing acceptance of innovative neurological diagnostic instruments in this particular geographical area is contributing to the expansion of the market in this region.
Europe is anticipated to exhibit a CAGR of 6.3% over the forecast period due to several factors, including the growing elderly population, increased government spending on autoimmune illnesses, the presence of disposable income, and a rising prevalence of tobacco consumption within the area. In 2022, a significant proportion of the European Union (EU) population, specifically 21.1%, comprised individuals aged 65. The median age of the European Union's population has been on the rise, reaching 44.4 years as of 1 January 2022. This indicates that precisely half of the EU's population surpasses 44.4 years. This demographic is anticipated to have an impact on the market. Additionally, it is worth noting that in 2022, the European Union (EU) recorded a median disposable income of 18,706 purchasing power standards (PPS) per individual.
Furthermore, it is worth noting that the World Health Organization (WHO) European Region exhibits the greatest incidence of tobacco smoking among adults on a global scale, with a prevalence rate of 28%. This region also demonstrates one of the highest rates of smoking prevalence among women, standing at 19%. Tobacco consumption not only leads to adverse health outcomes and mortality but also catalyzes health disparities. The increase in tobacco smoking has been identified as a potential cause of lung cancer, which in turn is projected to contribute to the growth of the Paraneoplastic Syndrome Market during the forecast period.
The Asia-Pacific region is expected to experience rapid market growth due to the increasing incidence of paraneoplastic illness and cancer-related issues in developing nations and the rising disposable income and healthcare expenditure. In the year 2022, the World Health Organization's Southeast Asia Region documented over 2.2 million newly diagnosed instances of cancer, resulting in 1.4 million deaths attributed to the disease. These fatalities were over 10% of the total deaths within the region above. Lung cancer constituted 10.6% of the total number of deaths attributed to cancer.
The Middle East and Africa region is anticipated to exhibit the least market share within the global paraneoplastic syndrome market, based on the paraneoplastic syndrome market insights. This can be attributed to the limited progress, inadequate technical expertise, and substandard healthcare infrastructure prevalent in the emerging economies in this geographic area.
|Siemens Healthineers Koninklijke Philips General Electric Esaote NeuroLogica Masimo York Instruments Neusoft Medical Systems Canon Medical Systems
|U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
|China Korea Japan India Australia Singapore Taiwan South East Asia Rest of Asia-Pacific
|Middle East and Africa
|UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
|Brazil Mexico Argentina Chile Colombia Rest of LATAM
|Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global paraneoplastic syndrome market is segmented based on type, application, and region.
The market is further segmented by Type into Medication, Physical Therapy, and Speech Therapy.
Medication holds the major market share. The use of medications or pharmaceutical substances to manage and alleviate symptoms associated with paraneoplastic syndromes is referred to as medication. The drug used is determined by the individual's specific symptoms and complications. Medications include immunosuppressive drugs, corticosteroids, anti-inflammatory drugs, and other therapies to modify the immune response or target specific symptoms. The rising prevalence of paraneoplastic disease propels the global paraneoplastic syndrome market forward. Medication is projected to continue to dominate the market because of its wide availability, effectiveness, and requirement in combination with other therapies.
Exercise stretches and other physical interventions are used in physical therapy to increase mobility, reduce discomfort, and improve general physical function in people with paraneoplastic syndromes. Physical therapists collaborate with patients to treat specific movement issues caused by the syndrome. Individuals suffering from paraneoplastic syndromes can benefit from physical therapy to improve their quality of life and functional independence.
The segment can be bifurcated by application into Hospitals, Clinics, and Ambulatory Surgical Centers.
Hospitals account for the largest share of the market. Hospitals are major healthcare facilities with extensive medical facilities and various specialized departments. Hospitals serve as key facilities for diagnosing, treating, and caring for individuals suffering from paraneoplastic disorders. They offer various treatments, such as medical imaging, laboratory testing, surgery, and intensive care, making them ideal for dealing with difficult paraneoplastic syndromes.
Clinics are healthcare facilities that provide medical services to outpatients on a lesser scale than hospitals. Clinics may provide diagnostic services, consultations with specialists, and outpatient treatment options in the setting of paraneoplastic disorders. Neurology or oncology clinics might specialize in specific elements of paraneoplastic syndrome diagnosis and management.